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invasion in human hepatocellular carcinoma
in vitro
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and Caterina Messa1Abstract
Background: Thrombocytopenia has been reported to be associated with small size HCCs, and thrombocytosis to
be associated with large size HCCs. The aim was to examine the effects of platelets in relation to HCC cell growth.
Methods: The effects of time-expired pooled normal human platelets were examined on human HCC cell line
growth and invasion.
Results: Blood platelet numbers increased with increasing HCC tumor size and portal vein invasion. Platelet extracts
enhanced cell growth in 4 human HCC cell lines, as well as cell migration, medium AFP levels and decreased
apoptosis. Cell invasion was significantly enhanced, using a Matrigel-coated trans-well membrane and3D (Real-Time
Imaging) invasion assay. Western blots showed that platelets caused enhanced phospho-ERK and phospho–JNK
signaling and anti-apoptotic effect with increase of Bcl-xL (anti-apoptotic marker) and decrease of Bid (pro-apoptotic
marker) levels. Their growth effects were blocked by a JNK inhibitor.
Conclusions: Platelets stimulated growth and invasion of several HCC cell lines in vitro, suggesting that platelets or
platelet growth factors could be a potential pharmacological target.
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Platelets have a key function in blood clotting. However, it
is increasingly recognized that they have other actions,
including in cancer biology. Thrombocytosis has been
reported to occur in association with solid tumors and
over 40% of patients with thrombocytosis without iron
deficiency anemia have occult metastasis, typically of
the gastrointestinal system, breast, lung and ovary re-
views: [1-4]. Cancer can result in altered coagulation
and platelet activity and conversely, platelets have the
ability to influence cancer growth and metastasis [2,5].
This can occur by direct platelet effects or through
mesenchymal interactions [6,7].* Correspondence: brianicarr@hotmail.com
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stated.Platelets have also been reported to enhance liver regen-
erative growth in animals and hepatocyte proliferation
in vitro [8,9]. Conversely, thrombocytopenia can blunt
regeneration [10]. Human hepatocellular carcinoma (HCC)
typically arises on the basis of cirrhosis, most commonly
caused by hepatitis B or C or alcoholism, exposure to food
contamination by mycotoxins or to obesity. The fibrosis
that is a key aspect of cirrhosis, eventually causes portal
hypertension and associated splenomegaly, that is thought
to cause subsequent thrombocytopenia. Thrombocytopenia
of cirrhosis has recently been shown to be associated pre-
dominantly with small size HCCs [11], whereas very large
size HCCs often have normal platelet counts [12] and
thrombocytosis in HCC patients occurs most often with
large size tumors [13]. We have therefore examined the
effects of platelet extracts on the growth in vitro of human
HCC cell lines and report that they enhance cell prolifera-
tion, migration and invasion.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Cells and materials
PLC/PRF/5, Hep3B and HepG2 cells were obtained
from the ATCC and were cultured as we previously
described [14].
Platelet lysates
Apheresis platelets were collected from six healthy blood
donors after obtaining their consent and the approval of
the Ethics Committee of Institute “Saverio de Bellis” and
University of Bari, Italy. The human platelet-rich plasma
(PRP) was obtained using an automated haemapheresis
procedure in a local blood transfusion center.
The platelets were subjected to several freeze-thaw cycles
to disrupt their membranes and release the growth factors
stored in the granules (human Platelet Lysate, hPL).
Growth and migration assays
Proliferation and migration assays were performed as re-
cently described [14]. The JNK inhibitor (SP600125; Sell-
eck Chemicals, Houston, TX, USA) 20 μM was used to
antagonize cell growth in presence of hPL or FBS.
AFP measurement
Medium AFP levels were measured using an automated sys-
tem (UniCel Integrated Workstations DxC 660i, Beckman
Coulter, Fullerton, CA, USA) by a chemioluminescent
immunometric method. Sample measurements over the
calibration range were automatically re-analyzed accord-
ing to manufacture’s instructions.
Apoptosis assays
Annexin V
The Muse Annexin V/Dead Cell Assay Kit (Millipore,
Darmstadt, Germany) for quantitative analysis of live,
early/late apoptotic and dead cells was used with a Muse
Cell Analyzer (Millipore). Briefly, the assay utilizes Annexin
V to detect PS on the external membrane of apoptotic cells.
A dead cell marker (7-AAD) is also used. PLC/PRF/5 cell
line, including positive and negative controls, were cultured
in 1% FBS medium supplemented with a volume of hPL
corresponding to 3.75×107platelets/ml or with an equiva-
lent percentage of serum (control cells) for 48 h. The cells
were then processed as described in the user’s guide.
Caspase-3/7 quantitative measurements
The Muse Caspase-3/7 kit (Millipore) permits simultan-
eous evaluation of apoptotic status based on Caspase-3
and −7 activation and cellular plasma membrane per-
meabilization (cell death).
The assay provides relative percentage of cells that are
live, early/late apoptotic or dead. Cells were cultured
as described above and processed according to the user’s
guide.Matrigel invasion assay
Huh7-GFP cells were generated by infection with retroviral
particles containing pLXSN-GFP vector (Clontech Labora-
tories, Mountain View, CA, USA) and isolated by neomycin
selection without clonal propagation.
Invasion was performed as previously described [15].
Briefly, 8 μm trans-well membranes (Corning Life Sciences,
Manassas, VA, USA) were pre-coated with 20 μg/ml BD
Matrigel™ Basement Membrane Matrix (BD Biosciences,
Buccinasco (MI), Italy).
Huh7-GFP cells were trypsinized and loaded (1 × 105
cells) into the upper chamber of the trans-well plates and
allowed to invade for 24 h. After fixation with 4% parafor-
maldehyde, invaded cells were quantified by counting the
GFP-positive cells.
Real-time imaging of the 3D Matrigel invasion
For 3D experiments, Huh7-GFP were trypsinized, counted
and seeded on the top of the lower polymerized Matrigel
layer and allowed to adhere and spread. After 3 h, the
same cold Matrigel solution was added to cover the cells
and to form the upper layer of the 3D Matrigel. Following
polymerization, an appropriate dilution of hPL in DMEM
medium or DMEM containing 1% BSA was added to
the wells. The motility of invasive cells within the 3D
Matrigel was monitored by real-time imaging with a modi-
fied epi-illumination Zeiss microscope (Zeiss, Oberkochen,
Germany) equipped with a Hamamatsu CCD camera
(ORCA-AG; Hamamatsu Photonics, Hamamatsu city,
Japan). Digital images were acquired using AxioVision
imaging software (Zeiss, Jena, Germany) and further
processed using Photoshop software (Adobe, San Jose,
CA, USA).
Western blots
We analyzed the MAPK signaling and anti-apoptosis
markers in PLC/PRF/5 cells treated with hPL by Western
blot, exactly as previously described [14]. In brief, cells
were washed twice with cold PBS and then lysed in RIPA
buffer (Sigma-Aldrich, Milan; Italy). After quantization of
protein concentration, equal amount of protein (50 μg)
were resolved on SDS–PAGE and transferred to polyvinyl-
difluoride (PVDF) filters. The blots were blocked with 5%
(w/v) nonfat dry milk for 2 h at room temperature and
then probed with primary antibody overnight at 4°C.
The primary antibodies were directed against the fol-
lowing proteins: ERK and phospho-ERK (p-ERK), JNK
and phospho-JNK (p-JNK), STAT3 and phospho-STAT3
(Tyr705, Ser727) (pSTAT3), phospho-p38 MAPK (p-p38)
and p38 MAPK, AKT and phospho-AKT (p-AKT), Bid,
Bcl-xL and β-actin (Cell Signaling, Beverly, MA, USA).
Immunoreactive bands were visualized and analyzed using-
enhanced chemiluminescence detection reagents (Cell
Signaling, Beverly, MA, USA) and a chemiluminescence
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Milan, Italy). Results were representative of 3 independent
experiments.
In vitro experimental data
The differences between two unmatched groups were
evaluated by Mann–Whitney nonparametric test.
For multiple comparisons was used one-way Anova test
followed by Dunnett's post test.
The computer software used was GraphPad Prism
version 5.0.
P-values of <0.05 were considered statistically significant.Figure 1 Effects of platelet extracts on HCC cell line growth. (A) Compari
cultured in different FBS percentage (0-5%) for 48 h in presence of PLTs or equ
difference in growth is detected only at 1% FBS. (B-E) Effects of platelets on th
Hep3B (D) and Huh7 (E) cell lines were cultured in 1% FBS medium in presenc
after 48 h. (F) Comparison of different concentrations of red cells (RBC), white c
MTT assay. (G) Comparison of time windows (0-24 h, 0-48 h, 48-72 h, 24-72 h a
evaluated after 72 h by MTT assay. The results are expressed as mean ± SD. *PAll experiments were done in triplicate and data are
presented as mean ± standard deviation (mean ± SD).
Results
Platelets as a source of HCC growth stimulants
hPL were examined for the ability to stimulate human
HCC cell line growth. PLC/RFP/5 cells were cultured in
different FBS concentrations (0-5%) for 48h in presence of
hPL or equivalent FBS concentration (control) in order to
define the minimum FBS concentration to maintain the
health of cells without growth. Comparing the growth
in presence of hPL or FBS by MTT assay, a significantson of serum concentrations on platelet actions. PLC/RFP/5 cells were
ivalent FBS concentration (control). Performing MTT assay, a significant
e growth of different human HCC cell lines. PLC/PRF/5 (B), HepG2 (C),
e of different platelets concentrations or FBS and MTT assay was assessed
ells (WBC) and platelets on PLC/PRF/5 cell growth evaluated after 48 h by
nd 0-72 h) for effects of two different platelet concentrations on growth
< 0.05; **P < 0.001; ***P < 0.0001.
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low serum concentration was used in all further platelet
lysate experiments, as higher serum concentrations
caused maximum cell growth stimulation.
PLC/PRF/5, HepG2, Hep3B or Huh7-GFP cell lines were
cultured in 1% FBS in presence of different hPL concentra-
tions or FBS (control). Cell growth was enhanced by culture
with hPL (Figure 1B-E). This growth stimulation was
reversible, since sub-culture of the same treated cells with-
out further addition of platelet extracts, resulted in a return
to normal pre-treatment growth (data not shown).Figure 2 Effects of platelets on PLC/PRF/5 cells. (A) AFP levels in the ce
platelets concentrations or FBS. (B) Migration assay. PLC/PRF/5 cells were tr
analyzed at the time of the scratch and after 72 h. Values were expressed a
wound. (C) Apoptosis assays. On the left are shown examples of results ob
(lower panel) to evaluate the percentage of apoptotic PLC/PRF/5 cells cultu
experiments is plotted in the relative graph. The results are expressed as mCharacterization of hPL effects on cell growth
The effects of platelets on cell growth were examined
further. Neither red cell (RBCs) nor white cell extracts
(WBCs) had similar HCC growth stimulatory effects as
platelets (Figure 1F).
To determine the time of exposure needed for platelets
to enhance cell growth, cells were exposed to hPL for
various time windows. A minimum of 48 h was found
to be necessary (Figure 1G). Alpha-fetoprotein (AFP) is
a secreted HCC protein that is commonly used as a
measure of HCC growth and aggressiveness. We foundll culture medium of PLC/PRF/5 cell lines after treatment with different
eated with different platelet concentrations or FBS and microscopically
s percentage of migration, 100% representing the completely closed
tained using the Muse Annexin V kit (upper panel) or Caspase-3/7 kit
red whit PLTs or FBS. On the right the mean of three independent
ean ± SD. *P < 0.05; ***P < 0.0001.
Figure 3 (See legend on next page.)
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Figure 3 Effects of platelets on hepatocellular carcinoma cell motility and invasion. (A) Huh7-GFP cells were assayed by Matrigel
chemo-invasion with BSA 1% (control) or different dilution of platelet factors added to a lower compartment of the chamber at the
indicated concentrations. (B) Tracking the migration of Huh7-GFP cells by live optical imaging. GFP-expressing Huh7 were imaged for 16 h and the
behavior of motile cells was recorded. (C) The tracks of 6 representative cells (3 controls and 3 stimulated with platelet factors) are plotted inWind-rose
plots with the initial position of each track (left panel).Scale bar, 100 μm. The temporal increase in the productive motility of these representative tracks
from controls and stimulated Huh7-GFP cells are also plotted in the graph (right panel). (D) 3D Invasion assay of Huh7-GFP cells in the presence of
platelet soluble factors. The rate of cell migration was determined at different time intervals (6, 12, 24 h). Three representative tracks for each condition
(cells stimulated with platelet factors or with BSA 1% as control) are plotted in the graph. All experiments were carried out in triplicate. The results are
expressed as mean ± SEM. P values were determined by Mann–Whitney one-tailed test.
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after exposure to hPL (Figure 2A). Since cell growth is a
balance between growth stimulation and apoptosis, we
then examined the percent of apoptotic cells in cultures
with and without hPL and found that platelets decreased
the baseline percent of apoptotic cells (Figure 2C). Cell
migration was also investigated and also found to be
enhanced by exposureto platelet extracts (Figure 2B).
Platelet-enhancement of cell invasion
To further characterize a role for platelet factors in altering
HCC tumor motility, we carried out 2D and 3D invasion
assays using fluorescence labeled cells (Huh7-GFP). Using
preliminary 2D transwell invasion experiments, we found
that platelet factors increase tumor invasion of Huh7-GFP
compared to control (BSA 1%) and that dilution is an im-
portant factor in determining the increased (Figure 3A).
In fact, 1:10 dilution was the optimal concentration to
determine the highest effect on tumor cell motility. This
dose was used for the subsequent 3D experiments. The
advantage of the 3D real-time imaging analysis is that
individual cells could be tracked in real-time as shown
in Figure 3B. By using this technique, we found an increase
in cell motility in platelet factor-stimulated Huh7-GFP cells
compared with controls and this was corroborated by the
increase of productive migration (distance from the point
of origin) in platelet factor-treated Huh7-GFP compared to
controls (Figure 3C). The increased motility of individual
tumor cells was also measured as distance traveled by the
cells (expressed in μm) by the tracking of selected cells at
different time intervals (Figure 3D).
Mechanisms associated with growth stimulation by platelets
Western blotting was performed on extracts of cells treated
without (controls) or with hPL for common MAPK path-
ways associated with growth stimulation, and for anti-
apoptosis mediators (Figure 4A-B). We found an increase
in p-ERK levels, and especially in p-JNK levels, but not in
p-p38 levels, together with an increase in p-STAT3 levels.
The anti-apoptotic effect was associated with two dif-
ferent mechanisms: an increase of Bcl-xL (anti-apoptotic
marker) levels and a decrease of Bid (pro-apoptotic
marker) levels. To test the significance of the strong p-JNKinduction, cell growth enhancement by hPL was repeated
in the presence or absence of a JNK inhibitor, which abro-
gated the stimulatory effects of hPL (Figure 4C).
Discussion
There have been several studies of the interactions
between blood platelets and tumor biology for several
human cancers, including ovarian, breast and colon cancer
[4,6,16,17]. Several mechanisms have been proposed to
be involved, including altered cell adhesion, enhanced
coagulation and platelet-derived inflammatory cytokines,
angiogenesis factors and and/or tumor growth factors.
Thus, platelet changes can occur in conjunction with co-
agulation changes in response to the growth of tumors,
and conversely, platelets may be involved in tumor growth
and metastasis [18,19]. To our knowledge, the current
report is a first of a direct effect of platelets on HCC cell
growth and invasion. We found that extracts of pooled
normal human platelets stimulated growth of several hu-
man HCC cell lines in vitro, as well as cell migration and
invasion. The effects were time-dependent and reversible,
as subsequent sub-culture of platelet-treated cells without
platelets, led to loss of the growth stimulant effects. Culture
medium AFP levels were also increased with growth stimu-
lation, and low baseline cell apoptosis levels were further
reduced by exposure to platelet lysates. The clinical findings
of enhanced incidence of portal vein thrombosis in the
presence of larger tumors with higher platelet counts, led
us to also study cell motility. Cell migration was increased
using two different cellular models, an cell invasion was
evaluated using Matrigel-treated membranes. The Western
blot analysis showed an increase in p-ERK, p-STAT3 and
especially p-JNK levels. A JNK inhibitor abrogated the
growth stimulatory actions of the platelet extracts, show-
ing the importance of this pathway in the platelet growth
enhancing effects. Platelets and platelet-derived growth
factors have been previously described to have effects on
growth of hepatocytes [8-10,20-22].
Platelets and their products also influence HCC growth
and biology [23-29], but a direct effect has not been previ-
ously reported and platelet-inhibition has recently been
shown to antagonize hepatocarcinogenesis [30], likely in
this model through modulation of necro-inflammation.
Figure 4 Cell signaling changes induced by platelets. (A) Analysis of changes in p-ERK, p-JNK, p-STAT3, p-p38 and p-AKT. PLC/PRF/5 cells were treated
with 3.75 × 107 PLTs or FBS for different times. The changes in protein expression were evaluated using Western blot (WB) analysis. (B) The Western blot
(WB) analysis confirmed the anti-apoptotic effect of platelets as showed in Figure 2C. (C) To test the significance of p-JNK increase, observed in WB
analysis (A), on platelet-mediated growth induction, SP600125 (JNK inhibitor) was used, resulting in inhibition of PLT action. *P < 0.05.
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carcinogenesis has been reported in association with
carcinogen-induced platelet proteome changes [31]. Plate-
let factors that might be involved in HCC growth include
inflammatory cytokines, Vascular endothelial growth fac-
tor (VEGF), Fibroblast growth factor (FGF), serotonin and
Platelet-derived growth factors (PDGF).
Platelets and their extracts have been recently used
therapeutically for their growth enhancing and wound heal-
ing effects [32-34], and they contain multiple growth factors
including Insulin-like growth factor-1 (IGF-1), Epider-
mal growth factor (EGF), Transforming growth factor beta(TGFβ), PDGFs, FGFs, VEGFs, serotonin and interleukins.
Identification of the platelet factors, which were involved
in the growth stimulation reported here, is beyond the
scope of this study. These same factors that have thera-
peutic healing potential for normal cells and tissues, can
also worsen tumor growth. This has led to the evaluation
of aspirin, a platelet modulator, both for its effects in inhi-
biting experimental HCC [30,34-37], but also in clinical
trials for cancer risk reduction and metastasis reduction
[37]. Platelet modulation has also been reported as affecting
metastasis [20,38,39], and platelets have been shown to
enhance cell migration and invasion [40,41]. Thus, the
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cation in both HCC prevention and in improving HCC
biology, in patients without thrombocytopenia or other
bleeding disorder.
Conclusions
Extracts from normal human platelets, but not from red or
white blood cells, could stimulate growth in vitro in several
human HCC cell lines. The extracts also stimulated HCC
cell migration and invasion. They inhibited apoptosis,
by both decreasing apoptotic effectors and inducing
anti-apoptotic mediators. p-JNK levels were elevated
by hPL actions and JNK was a likely mediator of the
hPL growth induction, since the growth increase was
antagonized by addition of a JNK inhibitor to the hPL.
Platelets therefore represent an additional potential
micro-environmental factor in HCC cell growth.
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